Patient clinical characteristics
. | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . |
|---|---|---|---|---|---|---|---|---|
| Patient diagnosis | SCD | SCD | SCD | SCD | CLL | HL | CLL | NHL |
| Patient age/sex | 34/F | 52/M | 5/M | 8/M | 64/M | 36/F | 51/M | 50/M |
| Donor sickle genotype/sex | Sickle trait/M | Sickle trait/M | Sickle trait/M | β-thalassemia trait/M | —/F | —/M | —/F | —/F |
| Pt/Donor ABO type | A/O | O/B | O/O | B/AB | B/O | A/O | A/O | O/O |
| Transplant conditioning regimen | Flu/Bu* | Flu/Bu* | Flu/Bu/ATG/TLI† | Flu/Bu/ATG/TLI† | Flu/Bu* | Flu/Bu/ATG* | Flu/Bu* | Flu/Bu* |
| Stem-cell source | PBSC | PBSC | BM | BM | PBSC | UCB | PBSC | PBSC |
| CD34+ cells/kg infused | 3.5 × 106 | 7.3 × 106 | 3.5 × 106 | 4.72 × 106 | 9.8 × 106 | 0.38 × 106 | 3.4 × 106 | 12.9 × 106 |
| GVHD prophylaxis | Tac/Pred | Tac/Pred | CsA/MMF | CsA/MMF | Tac/MTX | Tac/Rapa | Tac/MTX | Tac/Rapa |
. | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . |
|---|---|---|---|---|---|---|---|---|
| Patient diagnosis | SCD | SCD | SCD | SCD | CLL | HL | CLL | NHL |
| Patient age/sex | 34/F | 52/M | 5/M | 8/M | 64/M | 36/F | 51/M | 50/M |
| Donor sickle genotype/sex | Sickle trait/M | Sickle trait/M | Sickle trait/M | β-thalassemia trait/M | —/F | —/M | —/F | —/F |
| Pt/Donor ABO type | A/O | O/B | O/O | B/AB | B/O | A/O | A/O | O/O |
| Transplant conditioning regimen | Flu/Bu* | Flu/Bu* | Flu/Bu/ATG/TLI† | Flu/Bu/ATG/TLI† | Flu/Bu* | Flu/Bu/ATG* | Flu/Bu* | Flu/Bu* |
| Stem-cell source | PBSC | PBSC | BM | BM | PBSC | UCB | PBSC | PBSC |
| CD34+ cells/kg infused | 3.5 × 106 | 7.3 × 106 | 3.5 × 106 | 4.72 × 106 | 9.8 × 106 | 0.38 × 106 | 3.4 × 106 | 12.9 × 106 |
| GVHD prophylaxis | Tac/Pred | Tac/Pred | CsA/MMF | CsA/MMF | Tac/MTX | Tac/Rapa | Tac/MTX | Tac/Rapa |
Pred indicates prednisone; CsA, cyclosporine; MMF, mycophenylate mofetil; MTX, methotrexate; Rapa, rapamycin; Tac, tacrolimus; PBSC, peripheral-blood–derived stem cells; BM, bone marrow; and UCB, umbilical cord blood.
Fludarabine, 30 mg/m2 × 4 days; busulfex, 3.2 mg/kg
Fludarabine, 30 mg/m2 × 4 days; busulfan, 6.4 mg/kg; antithymocyte globulin, 30 mg/kg/dose IV daily × 5 days; and total lymphoid irradiation, 500 cGy with shielding of the liver, lungs, heart, and gonads